Search results for "Tumor markers."

showing 3 items of 23 documents

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

2013

Journal article TERT-locus SNPs and leukocyte telomere measures are reportedly associated with risks of multiple cancers. Using the Illumina custom genotyping array iCOGs, we analyzed ~480 SNPs at the TERT locus in breast (n = 103,991), ovarian (n = 39,774) and BRCA1 mutation carrier (n = 11,705) cancer cases and controls. Leukocyte telomere measurements were also available for 53,724 participants. Most associations cluster into three independent peaks. The minor allele at the peak 1 SNP rs2736108 associates with longer telomeres (P = 5.8 × 10!-7), lower risks for estrogen receptor (ER)-negative (P = 1.0 × 10!-8) and BRCA1 mutation carrier (P = 1.1 × 10!-5) breast cancers and altered promot…

TelomeraseMessengerCàncer d'ovariEstrogen receptorAetiology screening and detection [ONCOL 5]0302 clinical medicineBreast cancerRisk FactorsAlternative Splicing; Biomarkers Tumor; Breast Neoplasms; Case-Control Studies; Chromatin; DNA Methylation; Female; Gene Expression Profiling; Genetic Loci; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Luciferases; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Polymorphism Single Nucleotide; RNA Messenger; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Telomerase; Telomere; GeneticsGenotypeBUCCAL CELLSLuciferasesTelomeraseOligonucleotide Array Sequence AnalysisOvarian Neoplasms0303 health sciencesTumorTelòmerReverse Transcriptase Polymerase Chain ReactionGENETIC-VARIATIONCOMMON VARIANTSSingle Nucleotidetert-clptm1l locus; genome-wide association; genetic-variation; susceptibility loci; buccal cells; fibroblasts; common variants; carcinoma; reverse-transcriptase htert; metaanalysisTelomereAetiology screening and detection Immune Regulation [ONCOL 5]Chromatin3. Good healthTumor Markers Biological030220 oncology & carcinogenesisFemaleFIBROBLASTSGenotypeSUSCEPTIBILITY LOCICARCINOMASingle-nucleotide polymorphismBreast NeoplasmsBiologyReal-Time Polymerase Chain ReactionPolymorphism Single NucleotideArticleCàncer de mama03 medical and health sciencesBreast cancerSDG 3 - Good Health and Well-beingTranslational research [ONCOL 3]Ovarian cancermedicineGeneticsBiomarkers TumorHumansGenetic Predisposition to DiseaseRNA MessengerPolymorphismAlleleGENOME-WIDE ASSOCIATIONMETAANALYSIS030304 developmental biologyMolecular epidemiology Aetiology screening and detection [NCEBP 1]Breast cancer susceptibilityHereditary cancer and cancer-related syndromes [ONCOL 1]Translational research Genomic disorders and inherited multi-system disorders [ONCOL 3]Gene Expression ProfilingDNA Methylationmedicine.diseaseMolecular biologyTERT-CLPTM1L LOCUSTelomereMinor allele frequencyAlternative SplicingGenetic LociCase-Control StudiesRNABiomarkersREVERSE-TRANSCRIPTASE HTERTGenome-Wide Association StudyNature genetics
researchProduct

Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models

2019

Patient‐derived xenograft (PDX) models have become an important asset in translational cancer research. However, to provide a robust preclinical platform, PDXs need to accommodate the tumor heterogeneity that is observed in patients. Colorectal cancer (CRC) can be stratified into four consensus molecular subtypes (CMS) with distinct biological and clinical features. Surprisingly, using a set of CRC patients, we revealed the partial representation of tumor heterogeneity in PDX models. The epithelial subtypes, the largest subgroups of CRC subtype, were very ineffective in establishing PDXs, indicating the need for further optimization to develop an effective personalized therapeutic approach …

Tumor Markers and SignaturesCMSShort Reportcolorectal cancerXenograft Model Antitumor AssaysDisease Models AnimalMicecell proliferationxenograft CMStumor subtypeAnimalsHeterograftsHumansxenograftColorectal NeoplasmsPDX
researchProduct

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

2010

Abstract The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n = 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive …

glycoproteinMaleTime FactorsZAP-70Chronic lymphocytic leukemiavascular endothelial growth factor aBiochemistryGastroenterologyimmunoglobulin heavy chainsAdult Aged Aged; 80 and over Angiopoietin-2; analysis/blood Blood Chemical Analysis Female Humans Leukemia; Lymphocytic; Chronic; B-Cell; blood/diagnosis/mortality/therapy Male Middle Aged Neoadjuvant Therapy Prognosis Survival Analysis Time Factors Tumor Markers; Biological; bloodBlood plasma80 and overChronicTumor MarkersAged 80 and overLeukemiaHematologyHazard ratioprotein kinaseHematologyanalysis/bloodMiddle Agedchronic b-cell leukemiasPrognosisLymphocyticNeoadjuvant TherapyLeukemiaCohortFemaleAdultmedicine.medical_specialtyImmunologyangiopoietins chronic b-cell leukemias chronic lymphocytic leukemia plasma vascular endothelial growth factor a cd38 enzyme-linked immunosorbent assay glycoprotein immunoglobulin heavy chains protein kinaseNOcd38Angiopoietin-2bloodInternal medicinemedicineBiomarkers Tumorchronic lymphocytic leukemia angiopoietin-2.Humansbeta(2)-microglobulinplasmaSurvival analysisblood/diagnosis/mortality/therapyAgedbusiness.industryB-CellCell BiologyBiologicalmedicine.diseaseLeukemia Lymphocytic Chronic B-CellSurvival AnalysisConfidence intervalImmunologychronic lymphocytic leukemiaangiopoietin-2enzyme-linked immunosorbent assaybusinessCLL; angiopoietin-2; beta(2)-microglobulin; ZAP-70; CD38Settore MED/15 - Malattie del SangueangiopoietinsBlood Chemical AnalysisCLLCD38Blood Chemical Analysis; Angiopoietin-2; Humans; Neoadjuvant Therapy; Prognosis; Aged; Aged 80 and over; Leukemia Lymphocytic Chronic B-Cell; Adult; Middle Aged; Tumor Markers Biological; Time Factors; Female; Male; Survival Analysis
researchProduct